MTOR F2108L
|
Thyroid Gland Anaplastic Carcinoma
|
MTOR F2108L
|
Thyroid Gland Anaplastic Carcinoma
|
everolimus Resistant: C4 – Case Studies
|
everolimus Resistant: C4 – Case Studies
|
MTOR F2108L
|
Thyroid Gland Carcinoma
|
MTOR F2108L
|
Thyroid Gland Carcinoma
|
Torin1 Sensitive: D – Preclinical
|
Torin1 Sensitive: D – Preclinical
|
MTOR F2108L
|
Thyroid Gland Carcinoma
|
MTOR F2108L
|
Thyroid Gland Carcinoma
|
sirolimus Resistant: D – Preclinical
|
sirolimus Resistant: D – Preclinical
|
MTOR F2108L
|
Breast Cancer
|
MTOR F2108L
|
Breast Cancer
|
sirolimus Resistant: D – Preclinical
|
sirolimus Resistant: D – Preclinical
|
MTOR F2108L
|
Breast Cancer
|
MTOR F2108L
|
Breast Cancer
|
RapaLink-1 Sensitive: D – Preclinical
|
RapaLink-1 Sensitive: D – Preclinical
|